Opposite long-term regulation of c-Myc and p27Kip1 through overactivation of Raf-1 and the MEK/ERK module in proliferating human choroidal melanoma cells

Oncogene

Volumn 22, Issue 55, 2003, Pages 8813-8822

  Lefevre, Gaëlle ^a   Calipel, Armelle ^a   Mouriaux, Frédéric ^a   Hecquet, Christiane ^a   Malecaze, François ^b   Mascarelli, Frédéric ^a  

^a INSERM   (France)

^b CHU PURPAN   (France)

Author keywords

Antisense strategy; Choroidal melanoma; Proliferation; Raf 1

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ANTISENSE OLIGONUCLEOTIDE; ISOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MYC PROTEIN; PHOSPHOROTHIOIC ACID; PROTEIN P27; RAF PROTEIN; RAS PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; CELL CYCLE; CELL LINE; CELL PROLIFERATION; CELL STIMULATION; CHOROID MELANOMA; CONTROLLED STUDY; DOWNSTREAM PROCESSING; ENZYME ACTIVATION; EYE; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOCYTE; MELANOMA CELL; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; SERUM; SIGNAL TRANSDUCTION;

CELL CYCLE PROTEINS; CELL DIVISION; CHOROID NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE KINASE KINASE 1; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-MYC; PROTO-ONCOGENE PROTEINS C-RAF; TUMOR SUPPRESSOR PROTEINS;

EID: 0347363828     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1207099     Document Type: Article

References (34)

1. Alessi DR, Cuenda A, Cohen P, Dudley DT and Saltiel AR. (1995). J. Biol. Chem., 270, 27489-27494.
2. Barry OP, Mullan B, Sheehan D, Kazanietz MG, Shanahan F, Collins JK and O'Sullivan GC. (2001). J. Biol. Chem., 276, 15537-15546.
3. Casagrande F, Bacqueville D, Pillaire MJ, Malecaze F, Manenti S, Breton-Douillon M and Darbon JM. (1998). FEBS Lett., 422, 385-390.
4. Chang L and Karin M. (2001). Nature, 410, 37-40.
5. Chuang CF and Ng SY. (1994). FEBS Lett., 346, 229-234.
6. Coats S, Flanagan WM, Nourse J and Roberts JM. (1996). Science, 272, 877-880.
7. D'Agnano I, Valentini A, Fornari C, Bucci B, Starace G, Felsani A and Citro G. (2001). Oncogene, 20, 2814-2825.
8. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR and Futreal PA. (2002). Nature, 417, 949-954.
9. Gille H and Downward J. (1999). J. Biol. Chem., 274, 22033-22040.
10. Guise S, Braguer D, Carles G. Delacourte A and Briand C. (2001). J. Neurosci. Res., 63, 257-267.
11. Gupta S, Seth A and Davis RJ. (1993). Proc. Natl. Acad. Sci. USA, 90, 3216-3220.
12. Her JH, Wu J, Rail TB, Sturgill TW and Weber MJ. (1991). Nucleic Acids Res., 19, 3743.
13. Hoshino R, Tanimura S, Watanabe K, Kataoka T and Kohno M. (2001). J. Biol. Chem., 276, 2686-2692.
14. Hu DN, McCormick SA, Ritch R and Pelton-Henrion K. (1993). Invest. Ophthalmol. Vis. Sci., 34, 2210-2219.
15. Jamerson M, Johnson M and Dickson RB. (2000). Oncogene, 19, 1065-1071.
16. Kan-Mitchell J, Mitchell MS, Rao N and Liggett PE. (1989). Invest. Ophthalmol. Vis. Sci., 30, 829-834.
17. Kimura A, Ohmichi M, Kurachi H, Ikegami H, Hayakawa J, Tasaka K, Kanda Y, Nishio Y, Jikihara H, Matsuura N and Murata Y. (1999). Cancer Res., 59, 5133-5142.
18. Krueger JS, Keshamouni VG, Atanaskova N and Reddy KB. (2001). Oncogene, 20, 4209-4218.
19. Marshall CJ and Leevers SJ. (1995). Methods Enzymol., 255, 273-279.
20. Monia BP, Johnston JF, Geiger T, Muller M and Fabbro D. (1996). Nat. Med., 2, 668-675.
21. Mooy CM, Van der Helm MJ, Van der Kwast TH, De Jong PT, Ruiter DJ and Zwarthoff EC. (1991). Br. J. Cancer., 64, 411-413.
22. Mosmann TJ. (1983). Immunol. Methods., 65, 55-63.
23. Mouriaux F, Casagrande F, Pillaire MJ, Manenti S, Malecaze F and Darbon JM. (1998). Invest. Ophthalmol. Vis. Sci., 39, 876-884.
24. Mouriaux F, Maurage CA, Labalette P, Sablonniere B, Malecaze F and Darbon JM. (2000). Invest. Ophthalmol. Vis. Sci., 41, 2837-2843.
25. Pages G, Guerin S, Graill D, Bonino F, Smith A, Anjuere F, Auberger P and Pouyssegur J. (1999). Science, 286, 1374-1377.
26. Parrella P, Caballero OL, Sidransky D and Merbs SL. (2001). Invest. Ophthalmol. Vis. Sci., 42, 1679-1684.
27. Peyssonnaux C, Provot S, Felder-Schmittbuhl MP, Calothy G and Eychene A. (2000). Mol. Cell. Biol., 20, 7068-7079.
28. Pyrhonen S. (1998). Invest. Ophthalmol. Vis. Sci., 34 (Suppl 3), S27-30.
29. Sivaraman VS, Wang H, Nuovo GJ and Malbon CC. (1997). J. Clin. Invest., 99, 1478-1483.
30. Soparker CN, O'Brien JM and Albert DM. (1993). Invest. Ophthalmol. Vis. Sci., 34, 2203-2209.
31. Volmat V and Pouyssegur J. (2001). Biol. Cell, 93, 71-79.
32. Wang L, Liu F and Adamo M. (2001). J. Biol. Chem., 40, 37242-37249.
33. Weinstein-Oppenheimer CR, Blalock WL, Steelman LS, Chang F and McCubrey JA. (2000). Pharmacol. Ther., 88, 229-279.
34. Wilkinson MG and Millar JB. (2000). FASEB J., 14, 2147-2157.